Ticker: ARTL

Artelo Biosciences, Inc. (NASDAQ: ARTL) - quick read on what's happening inside the company Short summary: Artelo remains a clinical‑stage biotech advancing lipid‑signaling/cannabinoid programs (ART27.13, ART26.12, ART12.11) while aggressively funding operations through equity, convertible notes ...

Artelo Biosciences, Inc. (NASDAQ: ARTL) has recently reported financial results for the first quarter ended March 31, 2025. The company continues to focus on developing therapeutics that modulate lipid-signaling pathways, particularly through its key product candidates ART27.13 and ART26.12. Key ...